Edoxaban versus Warfarin in Patients with Atrial Fibrillation

20135,068 citationsJournal Articlebronze Open Access

Authors

Robert P. Giugliano · Brigham and Women's Hospital

Christian T. Ruff · Brigham and Women's Hospital

Eugene Braunwald · Brigham and Women's Hospital

Andrew W. Murphy · Harvard University

Stephen D. Wiviott · Brigham and Women's Hospital

Jonathan L. Halperin · Mount Sinai Medical Center

Albert L. Waldo

Abstract

Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 22, pp. 2093-2104

DOI: 10.1056/nejmoa1310907

Field-Weighted Citation Impact: 233.11